MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy trial aims to wipe out hidden leukemia cells
Disease control CompletedThis study tested an immunotherapy drug called blinatumomab in adults with a type of blood cancer (B-cell acute lymphoblastic leukemia) who were in remission but still had tiny amounts of cancer cells left. The goal was to see if the drug could help the immune system find and des…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Blood test guides precision strikes against lingering lung cancer
Disease control CompletedThis study tested a new strategy for controlling advanced lung cancer that has spread. It aimed to see if using a sensitive blood test to detect tiny amounts of leftover cancer could guide doctors to use targeted radiation or surgery on the remaining tumors. The goal was to see i…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New cancer vaccine targets 'Undruggable' KRAS mutations in early trial
Disease control CompletedThis early-stage trial tested a new immunotherapy called ELI-002 in 25 people with pancreatic, colorectal, lung, and other cancers that have specific KRAS mutations. The treatment was given after standard therapy to target any remaining cancer cells and prevent recurrence. Resear…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
First patients receive Lab-Grown immune cells in fight against leukemia
Disease control CompletedThis early-stage study tested the safety of a new treatment using lab-grown natural killer (NK) immune cells in adults with acute myeloid leukemia (AML) that has returned or is hard to treat, or who have minimal traces of disease. The main goal was to see if the treatment was saf…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC